Small molecule share of Phase I trial starts

Between 2016 and 2023, trials examining small molecule drugs in Phase I declined from 72% to 60% of trials before increasing to reach 62% in 2025.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

IQVIA Institute. (2016). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_WZ8SJC4F3Y3FTXMWY1GB2SGN91

Copy

MLA

IQVIA Institute. "Global R&D Trends 2026." 2016, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_WZ8SJC4F3Y3FTXMWY1GB2SGN91.

Copy

Chicago

IQVIA Institute. "Global R&D Trends 2026." 2016. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_WZ8SJC4F3Y3FTXMWY1GB2SGN91.

Copy

BibTeX

@misc{iqvia2016small2sgn91, author = {{IQVIA Institute}}, title = {Global R\&D Trends 2026}, year = {2016}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_WZ8SJC4F3Y3FTXMWY1GB2SGN91}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_WZ8SJC4F3Y3FTXMWY1GB2SGN91.